Double-Negative T Cell

A double-negative T cell (DN T cell) is a mature peripheral T lymphocyte that expresses the invariant CD3 signaling complex paired with a rearranged αβ or γδ T-cell receptor (TCR), yet lacks cell-surface expression of both the CD4 and CD8 coreceptors (CD3⁺CD4⁻CD8⁻) as well as invariant Natural Killer T (iNKT) and mucosal-associated invariant T cell (MAIT) lineage markers. Distinct from immature intrathymic double-negative (DN1–DN4) thymocyte progenitors that have not yet undergone β-selection, mature peripheral αβ DN T cells account for 1% to 3% of circulating peripheral blood T lymphocytes in healthy humans and mice. Characterized functionally by Li Zhang, Kun Yang, George C. Tsokos, and Joao B. Oliveira (2000–2022), peripheral αβ DN T cells occupy a dual immunological nexus: under physiological homeostasis and in adoptive cell therapy, regulatory DN T cells (DN Tregs) suppress alloreactive and autoreactive CD4⁺ and CD8⁺ T cells via Fas–FasL apoptosis, perforin/granzyme B, and cross-dressing (trogocytosis) to enforce transplant tolerance and prevent graft-versus-host disease; conversely, when extrinsic death-receptor apoptosis fails, CD3⁺TCRαβ⁺CD4⁻CD8⁻B220⁺CD45RA⁺ DN T cells expand in Autoimmune Lymphoproliferative Syndrome (ALPS) and secrete pathogenic interleukin-17 (IL-17) in Systemic Lupus Erythematosus (SLE).

In clinical flow cytometry and immunology, gating on CD3⁺CD4⁻CD8⁻ lymphocytes captures four developmentally distinct T-cell families that are separated using TCR chain and tetramer staining:

1. True Mature Peripheral αβ Double-Negative T Cells (CD3⁺TCRαβ⁺CD4⁻CD8⁻): Express a polyclonal or oligoclonal αβ TCR while testing negative for γδ TCR, CD1d–αGalCer tetramers (excluding Vα24-Jα18 iNKT cells), and MR1–5-OP-RU tetramers / Vα7.2⁺CD161^high (excluding MAIT cells). They represent 1% to 3% of human peripheral blood CD3⁺ T cells, lack the classical regulatory T-cell transcription factor FOXP3 (FOXP3⁻), and split into two functional states: immunoregulatory DN Tregs and pro-inflammatory/ALPS-associated DN T cells.
2. γδ T Lymphocytes (CD3⁺TCRγδ⁺CD4⁻CD8⁻): Account for 1% to 5% of circulating human T cells (predominantly Vγ9Vδ2⁺ in blood and Vδ1⁺ in mucosal epithelia); ~70%–80% of γδ T cells are constitutively CD4⁻CD8⁻ because γδ TCR recognition of phosphoantigens (via Butyrophilin 3A1/2A1) and stress ligands operates independently of classical MHC Class I and Class II.
3. Mucosal-Associated Invariant T (MAIT) and Invariant NKT (iNKT) Subsets: Roughly 10% to 20% of human MAIT cells (CD3⁺Vα7.2⁺CD161^highMR1-restricted) and up to 50% of iNKT cells (CD1d-restricted) lack both CD4 and CD8.
4. Intrathymic Double-Negative Thymocytes (DN1–DN4 Progenitors): Immature T-lineage precursors residing inside the thymic cortex prior to the CD4⁺CD8⁺ double-positive (DP) stage, staged in mice by CD44 and CD25 expression (DN1: CD44⁺CD25⁻ → DN2: CD44⁺CD25⁺ → DN3: CD44⁻CD25⁺ [β-selection checkpoint] → DN4: CD44⁻CD25⁻).

Lineage-tracing, TCR repertoire sequencing, and epigenetic methylation analyses (Crispín et al., 2008; Rodríguez-Rodríguez et al., 2015) demonstrate two convergent developmental pathways for peripheral CD3⁺TCRαβ⁺CD4⁻CD8⁻ DN T cells:

• Peripheral Conversion from Self-Reactive or Chronically Stimulated CD8⁺ T Cells: Many peripheral αβ DN T cells—particularly those expanding in autoimmune disease—derive from mature peripheral CD8⁺ T cells that have encountered high-affinity self-antigen and epigenetically silenced the CD8A and CD8B loci. As shown by George C. Tsokos and colleagues, chronic TCR stimulation upregulates the transcriptional repressor CREMα (cAMP Response Element Modulator alpha), which recruits DNA methyltransferase 3A (DNMT3A) and histone deacetylase 1 (HDAC1) to hypermethylate CpG islands in the CD8 cluster. Under normal peripheral tolerance, these reactivated cells are deleted via Fas (CD95) – Fas Ligand (CD95L) apoptosis; when Fas apoptosis is defective (as in ALPS), these post-CD8⁺ clones survive as B220 (CD45R)⁺CD45RA⁺PD-1⁺ DN T cells.
• Direct Thymic Agonist Selection (Thymic-Derived Regulatory DN T Cells): A second subset branches off during high-affinity agonist selection in the thymus, escaping clonal deletion without upregulating FOXP3 and entering the periphery as constitutive regulatory DN T cells (DN Tregs).

In 2000, Li Zhang and colleagues (Nature Medicine) discovered that peripheral CD3⁺TCRαβ⁺CD4⁻CD8⁻ DN Tregs suppress donor-specific allograft rejection and graft-versus-host disease (GVHD) through a two-step "acquire-and-kill" mechanism linked to cross-dressing (immunology):

1. Trogocytosis of Allo-MHC–Peptide Complexes from APCs: When a DN Treg contacts a donor dendritic cell, its αβ TCR binds cognate peptide–MHC complexes and extracts intact membrane patches containing those allo-MHC Class I or Class II–peptide complexes via trogocytosis, displaying the captured allo-MHC on the DN Treg's own surface.
2. Antigen-Specific Lysis of Syngeneic Effector T Cells: When alloreactive syngeneic CD8⁺ or CD4⁺ T cells bind the captured allo-MHC–peptide complex on the DN Treg's surface, the DN Treg kills them via Fas Ligand (CD95L) → Fas (CD95) and perforin / granzyme B (similar to CD4⁺ cytotoxic T cells), deleting alloreactive clones while sparing antiviral T cells. Ex vivo expanded allogeneic DN T cells have also entered clinical trials for relapsed acute myeloid leukemia (AML) via NKG2D/DNAM-1 tumor lysis without GVHD.

Conversely, in Autoimmune Lymphoproliferative Syndrome (ALPS) (Oliveira et al., 2010), germline or somatic mutations in FAS (TNFRSF6 / CD95), FASLG, or CASP10 prevent apoptosis of post-CD8⁺ cells, causing CD3⁺TCRαβ⁺CD4⁻CD8⁻B220⁺ DN T cells to expand to 5% to >40% of peripheral blood T cells (≥1.5% of total lymphocytes or ≥2.5% of CD3⁺ T cells is a mandatory NIH diagnostic criterion for ALPS, alongside elevated serum vitamin B₁₂, IL-10, and sFasL). Because ALPS DN T cells depend on mTORC1 signaling, the mTORC1 inhibitor sirolimus (rapamycin) induces rapid regression of lymphoproliferation and autoimmune cytopenias (Bride et al., 2016). In Systemic Lupus Erythematosus (SLE) (Crispín et al., 2008), expanded CREMα^highRORγt⁺ DN T cells secrete IL-17A, stimulate B-cell anti-dsDNA autoantibody production, and infiltrate the kidneys in lupus nephritis.

Why is it necessary to gate on TCRαβ⁺ when quantifying double-negative T cells to diagnose ALPS?

During acute viral infections (such as EBV or CMV), γδ T cells (CD3⁺TCRγδ⁺) expand to 5% to 15% of peripheral blood T cells, and ~80% of γδ T cells are naturally CD4⁻CD8⁻. Gating on CD3⁺TCRαβ⁺CD4⁻CD8⁻ (or excluding TCRγδ⁺) prevents a normal reactive γδ T-cell expansion from being misdiagnosed as ALPS.

Why does sirolimus (rapamycin) eliminate pathogenic DN T cells in ALPS when corticosteroids fail?

Pathogenic TCRαβ⁺B220⁺ DN T cells in ALPS lack functional Fas death receptors (making them resistant to steroid-induced extrinsic apoptosis), but they rely on constitutive mTORC1 signaling and aerobic glycolysis to survive. Sirolimus inhibits mTORC1, inducing mitochondrial apoptosis in ALPS DN T cells while sparing protective FOXP3⁺ regulatory T cells.

1. Zhang, Z. X., Yang, L., Young, K. J., DuTemple, B., & Zhang, L. (2000). "Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression." Nature Medicine, 6(7), 782–789. https://doi.org/10.1038/77513
2. Crispín, J. C., Oukka, M., Bayliss, G., Cohen, R. A., Van Beek, C. A., Stillman, I. E., Kyttaris, V. C., Juang, Y.-T., & Tsokos, G. C. (2008). "Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys." Journal of Immunology, 181(12), 8761–8766. https://doi.org/10.4049/jimmunol.181.12.8761
3. Oliveira, J. B., Bleesing, J. J., Dianzani, U., Fleisher, T. A., Jaffe, E. S., Lenardo, M. J., Rieux-Laucat, F., Siegel, R. M., Su, H. C., Teachey, D. T., & Rao, V. K. (2010). "Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop." Blood, 116(14), e35–e40. https://doi.org/10.1182/blood-2010-04-280347
4. Bride, K. L., Vincent, T., Smith-Whitley, K., Lambert, M. P., Bleesing, J. J., Seif, A. E., Manno, C. S., Casper, J., Grupp, S. A., & Teachey, D. T. (2016). "Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial." Blood, 127(1), 17–28. https://doi.org/10.1182/blood-2015-07-657981